The MHRA Has Approved a New Higher 7.2mg Wegovy Dose — Here Is What Changed and Why It Matters

The biggest myth: the 7.2mg pen is a brand-new medicine

A lot of coverage around the April 2026 MHRA announcement described it as though Wegovy itself had been upgraded. It hasn't. Wegovy is still semaglutide, still the same GLP-1 receptor agonist that Novo Nordisk has supplied for weight management since it received its UK licence. What changed was the presentation and the maximum dose ceiling.

The January 2026 decision confirmed 7.2mg as a licensed maintenance strength, but patients reaching that level needed three separate 2.4mg pens each week, cumbersome and easy to confuse. The April pen resolved that: one injection, one pre-set weekly dose, a built-in covered needle that locks after use. The mechanism is familiar to anyone already on the injection, and the titration path has not changed. You still begin at 0.25mg and move upward under a prescriber's guidance. The full Wegovy dosing schedule explains each stage, but the practical point here is that reaching 7.2mg takes months of careful stepping, not a single jump.

This matters because some readers arrive on pages like this hoping to start at the highest dose. If you want to understand exactly what that ceiling involves, the 7.2mg dose itself is covered in detail on its own page, including what patients and clinicians should know before reaching it. Clinicians design the slower schedule partly to give the body time to adjust to GI effects, and partly because some patients achieve the results they need at lower doses with a more manageable side-effect profile. The MHRA's 7.2mg approval is significant, but it is one step in a longer clinical journey.

Who the 7.2mg licence actually covers

Here is a narrowing that surprises people: the 7.2mg dose is licensed for adults with a BMI of 30 or above. The 2.4mg maintenance dose (the previous ceiling) was already available to adults with a BMI of 27–29.9 if they had at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnoea. The higher dose does not extend that lower-BMI eligibility band. If your BMI sits below 30, the 7.2mg pen is not licensed for you.

That said, eligibility is always a clinical assessment, not a calculator output. A prescriber considers your full health picture, other medicines you take, conditions that might affect tolerability, any history that changes the risk-benefit balance. The broader Wegovy overview covers the licensed eligibility criteria in full, and the background to the higher-dose approval gives more detail on how the regulator evaluated the evidence.

Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance, typically 2.5 kg/m² lower for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. A prescriber will apply those thresholds where relevant. BMI alone has never been a guarantee of approval, and the new dose does not change that principle.

What the trial data showed, and how to read it honestly

The evidence underpinning the 7.2mg approval came from clinical trials reporting an average weight loss of around 20.7% over 72 weeks. That figure put this dose closer to the results seen with tirzepatide at its highest strength in the SURMOUNT programme, which the NICE appraisal of tirzepatide (TA1026) discussed alongside indirect comparisons between treatments.

Around 20.7% is a group average. Some participants lost considerably more; others less. Trial populations are selected, drop-out is real, and results outside a trial setting depend on individual biology, lifestyle, and how consistently treatment is taken. Describing these figures as "what you will lose" would be wrong, and this page won't do that. What they show is that, for people who respond well to semaglutide and tolerate the escalating doses, the ceiling has moved meaningfully upward.

The most common side effects remain gastrointestinal: nausea, loose stools, indigestion, reduced appetite to the point of discomfort at times. These tend to be most noticeable after a dose step and often settle within a week or two. If you want to read about managing these in practice, the higher-dose patient information covers the side-effect picture in more detail, and the NHS's guidance on semaglutide is a solid first reference at NHS.uk/medicines/semaglutide.

One habit worth building before any Wegovy conversation

Before speaking to a prescriber about Wegovy, spend sixty seconds on the GPhC register at pharmacyregulation.org/registers and look up any pharmacy you're considering. A registered pharmacy has a premises number on the register. It takes less than a minute and rules out a significant slice of the counterfeit market, where pens sold without a prescription have caused hospitalisations. The MHRA has been clear in its guidance on the approved 7.2mg pen that legitimate supply flows through the licensed UK supply chain only, not social media, not unofficial importers, not sellers offering pens without clinical assessment.

The weight-loss treatments page is where to start if you'd like a prescriber at a GPhC-registered pharmacy to assess whether semaglutide (at any dose) is suitable for you. If you're still weighing options, the weight-loss treatment overview compares the available approaches. That decision belongs to you and a clinician together; this page's job is just to make sure the facts are accurate before that conversation begins.